$5.6M
2 filings since 2025 · latest Debt filed
Claris Biotherapeutics, Inc. is a pioneering biotechnology company dedicated to the development of innovative therapies specifically aimed at treating corneal diseases. With a particular focus on neurotrophic keratitis (NK), a rare and debilitating condition that can lead to significant vision loss, Claris is committed to addressing critical unmet medical needs in this niche area of ocular health.
What sets it apart
Claris stands out by leveraging its proprietary technology platform based on recombinant human variant hepatocyte growth factor (dHGF), aiming to not only treat neurotrophic keratitis but also potentially other corneal conditions.
CSB-001 is a topical ocular biologic solution that harnesses the regenerative properties of recombinant human variant hepatocyte growth factor (dHGF). This product is specifically engineered to promote and expedite healing in the cornea, which is vital for restoring vision in patients suffering from corneal diseases.
